ClinicalTrials.gg
CompletedNCT04266496DEVINeUpdated Jul 17, 2023

Discovering the Effect of Venous Insufficiency on Nocturia

An interventional study of Questionnaires and Frequency Volume Chart in Nocturia, Venous Insufficiency of Leg and Fluid Overload, sponsored by University Hospital, Ghent. Completed at 1 site in Belgium. Open to participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-07-17.

Sponsored by University Hospital, Ghent · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Non-randomized
Ages
25 Years to 60 Years
Sex
All
01

Study summary

With this prospective controlled trial, we hope to obtain more information about the coexistence between venous insufficiency and nocturia.

In our opinion, venous insufficiency (CEAP 2-3a) leads to an increase in fluid accumulation in the lower limbs due to moving around all day. When laying down during nighttime, this fluid is reabsorbed into the systimic fluid pool, leading to an increase in diuresis and thus an increase in nocturnal voiding. Aim of this study is observe difference in nocturnal frequency and urine production before and after surgical treatment of venous insufficiency.

02

Conditions studied

  • Nocturia
  • Venous Insufficiency of Leg
  • Fluid Overload

Browse trials for

03

In context

Nocturia

134 studies on the registry are indexed under Nocturia; 22 are open to participants now.

This study's enrollment of 84 is above the median of 71 across 108 interventional studies indexed under Nocturia.

Browse Nocturia studies →

Lead sponsor

University Hospital, Ghent is the lead sponsor of 689 studies on the registry; 160 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CEAP 2 till 4A

Exclusion criteria

Exclusion Criteria:

  • higher than 30
  • Previous surgery due to venous insufficiency at the lower limbs
  • Cronic edema (Cronic heart failure, liver cirrosis, nefrotic syndrome)
  • Pregnant patient
  • Patients on the following medication: Calcium-antagonists, lithium, NSAID's or , glitazones, insuline, diuretics, sartans, ACE-inhibitors, desmopressine,
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Other
    <2 nocturnal voids

    All interventions in this group are done twice: Once before surgical intervention, and once 2 months after surgical intervention * Complete a 3 day Frequency Volume chart * Questionnaires: ICIG FLUTS/MLUTS, PSQI and CIVIQ2

    Other: Questionnaires · Diagnostic Test: Frequency Volume Chart

  • Other
    => 2 nocturnal voids

    All interventions in this group are done twice: Once before surgical intervention, and once 2 months after surgical intervention * Complete a 3 day Frequency Volume chart and collection of the urine of the last day and night to complete osmolality and sodium testing. * Measuring the circumference off the lower limbs just after awakining and before falling asleep * Questionnaires: ICIG FLUTS/MLUTS, PSQI and CIVIQ2

    Other: Questionnaires · Diagnostic Test: Frequency Volume Chart · Diagnostic Test: Collect urine during 1 day · Diagnostic Test: Blood sample · Diagnostic Test: Measurement of the circumference of the lower legs

Interventions

  • OtherQuestionnaires

    ICIQ FLUTS (women) or MLUTS (mannen) CIVIQ 2 PSQI

  • Diagnostic testFrequency Volume Chart

    Collect a frequency volume chart for 3 days: measure the amount of voids and volume urinated.

  • Diagnostic testCollect urine during 1 day

    Volunteers are asked to collected their urine during the last day of the frequency volume chart. Volunteers get 2 jars: One for collection during the day, and 1 for overnight collection of urine. Osmolality and sodium of urine is tested

  • Diagnostic testBlood sample

    Blood collection to measure plasma sodium and osmolality.

  • Diagnostic testMeasurement of the circumference of the lower legs

    Circumference of the lower legs wil be measured twice: * After awakening, when still laying dowing in bed * Before goin to sleep Circumference should be measured 2 cm above the medial malleolus

06

What researchers measure

Primary outcomes

  1. Change of micturition frequency

    Change of the micturition frequency with 1 void

    Time frame: 2 months after surgery

Secondary outcomes

  1. Change in nocturnal diuresis

    Time frame: 2 months after surgery

07

Study locations

1 site
  • Department of urology
    Ghent, 8300, Belgium
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04266496
Responsible party
Sponsor
First posted
Feb 12, 2020
Start date
Jan 1, 2020
Primary completion
May 28, 2021
Completion
May 28, 2021
Last update
Jul 17, 2023

Study contacts

Karel Everaert, MD PhD
principal investigator · UZ Ghent

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion